Medikamentös bedingte Kardiomyopathien

Kardiovaskuläre Nebenwirkungen medikamentöser Therapien haben einen signifikanten Einfluss auf die Morbidität und Mortalität von Patienten. Dieser Beitrag gibt eine Übersicht über wichtige Substanzgruppen mit kardiotoxischen Nebenwirkungen und fasst Prinzipien der Diagnostik und Therapie zusammen. Eine gute Kenntnis der Charakteristika spezifischer kardialer Nebenwirkungen kann dazu beitragen, die Behandlung von Patienten zu verbessern.

Abstract

Drug-induced cardiovascular side effects have a significant impact on morbidity and mortality. The demographic change and improved long-term survival particularly in cancer patients have caused an increasing number of affected patients, hence emphasizing the importance of the best possible treatment of such complications. This article gives an overview of classic and modern groups of substances with cardiotoxic effects and summarizes the principles of diagnostics and therapy. After characterizing the common cardiovascular side effects caused by anthracycline chemotherapy, we focus on complications caused by modern forms of immunotherapy, considering its significant impact on oncological therapy in the future due to its growing clinical application. In addition to specific cancer therapies, accompanying measures such as blood transfusions in patients with hematologic diseases can also lead to severe cardiovascular complications. In the last section, we classify important features and therapeutic approaches in cardiac involvement of transfusion-related hemochromatosis. A good knowledge of the characteristics of specific cardiovascular side effects can help to improve the management of affected patients.

Schlüsselwörter

Hämochromatose - Immuncheckpoint-Inhibitor-Therapie - Kardiotoxizität - onkologische Kardiologie

Key words

cardio-oncology - cardiotoxicity - immune checkpoint inhibitor therapy - hemochromatosis

Publikationsverlauf

Artikel online veröffentlicht:
16. November 2022

• Literatur

• 1 Rassaf T, Totzeck M, Backs J. et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol 2020;
• 2 Totzeck M, Schuler M, Stuschke M. et al. Cardio-oncology – strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 2019; 280: 163-175
• 3 Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med 2020; 7: 26
• 4 Mincu RI, Mahabadi AA, Michel L. et al. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA network open 2019; 2: e198890
• 5 Totzeck M, Mincu RI, Heusch G. et al. Heart failure from cancer therapy: can we prevent it?. ESC heart failure 2019; 6: 856-862
• 6 Gongora CA, Drobni ZD, Silva TQAC. et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. J Am Coll Cardiol HF 2022; 10: 559-567
• 7 Tawbi HA, Schadendorf D, Lipson EJ. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 2022; 386: 24-34
• 8 Wang DY, Salem JE, Cohen JV. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4: 1721-1728
• 9 Mahmood SS, Fradley MG, Cohen JV. et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71: 1755-1764
• 10 Michel L, Totzeck M, Lehmann L. et al. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz 2020; 45: 645-651
• 11 DʼSouza M, Nielsen D, Svane IM. et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 2021; 42: 1621-1631
• 12 Michel L, Helfrich I, Hendgen-Cotta UB. et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 2022; 43: 316-329
• 13 Awadalla M, Mahmood SS, Groarke JD. et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol 2020; 75: 467-478
• 14 Totzeck M, Michel L, Lin Y. et al. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J 2022; 43: 1928-1940
• 15 Ghosh AK, Chen DH, Guha A. et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?. JACC CardioOncology 2020; 2: 97-109
• 16 Gulati V, Harikrishnan P, Palaniswamy C. et al. Cardiac involvement in hemochromatosis. Cardiol Rev 2014; 22: 56-68
• 17 Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Internal Med 2005; 143: 522-536
• 18 Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation 2011; 124: 2253-2263
• 19 Balkan C, Tuluce SY, Basol G. et al. Relation between NT-proBNP levels, iron overload, and early stage of myocardial dysfunction in β-thalassemia major patients. Echocardiography 2012; 29: 318-325
• 20 Aronow WS. Management of cardiac hemochromatosis. Arch Med Sci 2018; 14: 560-568